Caption Management’s Inhibrx INBX Stock Holding History

Caption Management’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57,500	Closed	-$1.94M	–	1814
2025 Q3	$1.94M	Buy	+57,500	New	+$1.42M	0.02%	857

Other funds holding INBX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caption Management's INBX Position: Q2 2026 in Review

Caption Management sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 1,000 shares — an estimated $100K sold.

Caption Management first reported a position in INBX in Q2 2024 and held it in 7 quarters. The position peaked at $3.13M in Q3 2024. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

Caption Management reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
Caption Management sold 1,000 Inhibrx shares in Q2 2026, an estimated $100K.
Caption Management first reported a position in Inhibrx in Q2 2024 and held it in 7 quarters.
Caption Management's Inhibrx position peaked at $3.13M in Q3 2024.
162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.